Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Up today with some volume (so far)… $5+ next...??? What I can see is that somebody is trying to get as many shares as they can without making too much noise... or at least, that's what a birdie told me.. !
Heavy bidding going on moving to the upside so far, either short covering or something may be coming down the tubes... !
Have you ever seen a 0.0044 going to 0.04, 0.40, 4.00, 40.00 ? Not on that specific order but it has happened... !
It might come down because I think their last quarter is not going to be impressive but, hopefully will re-emerge again with Oprah's next tours...
What I am saying is that if this stock was as bad as "some" try to paint here, people would dumping them and would probably be close to the bottom of the trips. There are still a lot of shares owned/held out there.
Happy days would be here again... !! :)
Then, who keeps buying this stock and what for...?
With the positive trials they have had so far with their protocol inventory this stock should be trading a lot much higher at it is now... the total outstanding shares is less than 20 million, I think app 16 now after their latest acquisition. Patience I guess... ! <sigh>
See latest filings...more institutional buying but the basic problem I see with this company is than they have very little clue as to how enhance shareholders' value... the release news of upcoming events and presentations but they don't follow up to let us know how those presentations and events went.... !! Their PR department stinks, you send them emails and they don't bother to answer.
What is this..???
And while on the subject of ZenaPay, what happened to those shares given to EPAZZ stockholders of ZenaPay which are still worthless... another scam from EPAZZ and its CEO?
Next big dump ?? I guess when you sit on the john next... ! lol
Just like the guy playing cards on the street.. now you see it, now you don't... !
Maybe they could try the NasoVax against the coronavirus.. ??
https://altimmune.com/nasovax/
Latest Forms 4 filed within the last few days...
https://ir.altimmune.com/investors/financials/sec-filings
I guess the promoters have not been paid lately.... ! <sigh>
Nothing like starting the day after a good dump.... !!
Wait till more solid news on their NASH and NasoVax start coming and you will see... !! In the meantime, Amazing Amazon.... !!! good thing I bought some options last month... !!!
You did it again.... this morning again?
At a higher price...? rather get them now... !!
Why..? everybody else is... and wonder why every time the stock is on the green side, there is a joker who throws 100 or 250 shares at the lower bid so that the stock gets on the "red" side...??
Try playing the Powerball tonight... lots of millions there for grab.. !
What's going on today with the trading... on the green side.. !
Do you...?
...I have zero clue what I am talking about...
Never mind the fake stocks of ZenaPay given away to investors and/or prospective investors of EPAZ last year... what a scam...!
What happened to the promoters..? gone again...?
But trading the stock still going on.... what's fueling it?
Very interesting... ! thanks for the link. I think the fat lady has no intentions to sing yet.... even some appear or trying to convince others that she will... IMO
We have a lot of time for this cancer drug to produce big earnings for the company...
From the news release of this morning:
The company also said the U.S. Patent and Trademark Office granted a patent for coverage for important elements of ALT-702 cancer immunotherapy product candidate. The issued patent will expire no earlier than 2034.
Read again... ! This is going to be a $20 or 30 stock not too long from now, IMO
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
January 23, 2020 at 7:00 AM EST
Preclinical study shows systemic activity of ALT-702 following local administration
Altimmune granted U.S. patent providing broad coverage of platform technology
GAITHERSBURG, Md., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity following intra-tumoral injection in an individual solid tumor.
The aggressive tumor model is based on the murine CT26 colorectal carcinoma cell line and involved the establishment of a tumor in each flank of a mouse. In the study, three doses of ALT-702 were injected into one tumor mass over 5 days with concomitant treatment with an anti-CTLA4 antibody immune checkpoint inhibitor administered intraperitoneally. Tumor regression was noted in both injected (88%) and non-injected (38%) lesions, and overall survival in the ALT-702 + anti-CTLA4 group was markedly better than either agent alone.
“These data represent a key milestone for the development of ALT-702 and are highly supportive of the immune-mediated antitumor activity of ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “ALT-702 represents a platform technology designed to be used with a variety of immune stimulants and we are excited about the potential of this approach in multiple tumor types.”
Additionally, the United States Patent and Trademark Office (USPTO) granted US Patent No. 10,434,183 (the ‘183 patent) entitled “Immunogenic Compound.” The ‘183 patent provides coverage for important elements of the Company’s ALT-702 cancer immunotherapy product candidate. The issued patent will expire no earlier than 2034. “The ‘183 patent is the second granted patent supporting ALT-702 and will provide further IP coverage for the ALT-702 development program. The Company was previously granted U.S. Patent No. 9,962,453 covering immunostimulatory compounds, including ALT-702.
About ALT-702
ALT-702 is a targeted tumor immunostimulant designed to act locally to reverse local immunosuppression within the tumor microenvironment and stimulate systemic antitumor immune responses. The ALT-702 technology is a novel synthetic peptide conjugate technology platform designed to retain and concentrate immunostimulants within a tumor leading to enhanced immune stimulation without the safety risk of systemic inflammation. ALT-702 represents a new approach in immuno-oncology that can act alone or improve the effectiveness of immune checkpoint inhibitors, oncolytic viruses or other approaches in immuno-oncology.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). For more information on Altimmune, please visit www.altimmune.com.
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the initiation of a Phase 1 clinical study in 2020, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to identify potential future government contracts or grant awards; the Company’s ability to obtain potential regulatory approvals on the timelines anticipated, or at all; the Company’s ability to obtain additional patents or extend existing patents on the timelines anticipated, or at all; the Company’s ability to identify and consummate potential future strategic partnerships or business combinations; the Company’s ability to expand its pipeline of products and the success of future product advancements, including the success of future clinical trials, and the Company’s ability to commercialize its products; and the Company’s anticipated financial or operational results; the Company’s ability to obtain additional capital resources; unforeseen safety and efficacy issues; breaches of data privacy, or disruptions in the Company’s information technology systems. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, which are available at www.sec.gov.
Contacts
And so are you.. ! Yawn... !!!
And the action keeps going... ! No doubt these clinical stages experimental companies are erratic and hard to predict but when one hits the right results, up they go to never now where, just look at to CCXI, trading quietly around $ 6-8 a couple of months ago, news came out and the rest is history. !!
Strange.. isn't ?? Yet, nobody falls for the bid, almost 400K shares at the bid and no one sells...??
Have no clue but something has to be the reason of today's volume and I don't think it's just short covering... !
Lot of interest, specially some trying to keep the share price in depression to make it look like a bad investment... yet, no one falls for the trap. A large bid shows up and it's silenced by small bid a bit higher.. lot of strange things on its way to the forum.. !
A simple mathematical equation:
LP x LK = 1
Did you get a reply yet?
It makes you feel like there is something more than meet the eyes....?
AWIHI Brad Loncar…?
Getting tired of this... next week, probably, can sell at a dime a get out... ! JMHO
Tell them to add a parachute just in case.. !!
Why would people be buying shares of a shell company? and the buying keeps going on... ! Would there be an interest to gain control of this "shell" and bring back what was set aside before? Just thinking out loud.
Who are you buying from...? I haven't seen that much selling... a few days back you claimed no one was paying more than 0.0025, this week some paid up to 0.0045... and the bid was a solid 0.0032... what's your plan?
Yes... I am selling this week.. I have 2 million shares and selling at whatever price I can get... 0.05, 0.04, 0.06...